EZH2相关科学文献

[1] EZH2: a novel target for cancer treatment， Duan et al. Journal of Hematology & Oncology (2020) 13:104

[2] The roles of EZH2 in cancer and its inhibitors，Yuankai Liu et al. Medical Oncology (2023) 40:167

[3] EZH2 inhibition: A promising strategy to prevent cancer immune editing. Epigenomics. 2020 Aug; 12(16): 1457–1476.

[4] EZH2-Targeted Therapies in Cancer: Hype or a Reality? Cancer Res. 2020 Dec 15;80(24):5449-5458. 

[5] EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023 Jun;4(6):872-892.

mRNA相关科学文献

[1] Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247(4949), 1465-1468.

[2] Katalin Karikó, Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of rna recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of rna. Immunity, 23(2), 165-175.

[3] Hou, X., Zaks, T., Langer, R., & Dong, Y. (2022). lipid nanoparticles for mrna delivery. Nature Reviews Materials, 6, 1078–1094.

[4] Mendes, B.B., Conniot, J., Avital, A. et al. (2022). Nanodelivery of nucleic acids. Nat Rev Methods Primers 2, 24.

[5] Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., & Gruber, W. C. (2020). Safety and efficacy of the bnt162b2 mrna covid-19 vaccine. The New England journal of medicine, 383(27), 2603-2615.

[6] Baden, L. R., Sahly, H. M. E., Essink, B., Kotloff, K., & Zaks, T. (2021). Efficacy and safety of the mrna-1273 sars-cov-2 vaccine. The New England journal of medicine, 384(5), 403-416.

[7] Sahin, U., Katalin Karikó, & zlem Türeci. (2014). Mrna-based therapeutics — developing a new class of drugs. Nature Reviews Drug Discovery, 13, 759–780.

[8] Shapiro, L., & Losick, R. (2021). Delivering the message: how a novel technology enabled the rapid development of effective vaccines. Cell, 184(21), 5271-5274.

[9] Kon E., Ad-El N., Hazan-Halevy I., Stotsky-Oterin L., Peer D. (2023). Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol.

[10] Namit C., Drew W., & Whitehead KA. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20, 817–838.

PROTAC 相关科学文献

[1] Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Liguo Wang  et al. Nature Chemical Biology, 2021, 17, 567-575.

[2] Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Longchuan Bai et al. Cancer Cell. 2019, 36, 498–511.

[3] Zimo Yang et al. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently. Cell Research, 2021, 31, 1315–1318.

[4] Atsunori Kaneshige et al. A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nature Chemical Biology. 2023, 19, 703–711.

[5] Xin Han et al.  Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J. Med. Chem., 2023, 66, 8822-8843.